Thymalfasin Plus TACE Explored for Unresectable Liver Cancer

Hepatocellular carcinoma (HCC) is a highly aggressive primary liver cancer, often diagnosed at advanced stages where curative options are limited. Trans arterial chemoembolization (TACE) is a standard palliative treatment for unresectable HCC, but its long-term efficacy can be suboptimal. This Phase II trial aimed to investigate if adding the immunomodulatory peptide thymalfasin (thymosin alpha-1) to TACE could improve outcomes for these challenging patients.

The provided trial registration (NCT00082082) outlines the study's objective and design but does not include any specific efficacy or safety results from the completed trial. Therefore, we cannot report quantitative data regarding patient outcomes, such as overall survival, progression-free survival, or tumor response rates. Similarly, specific adverse event profiles or their frequencies for either the thymalfasin plus TACE group or the TACE alone group are not detailed in this record. > The primary objective of this Phase II trial was to compare the efficacy and safety of thymalfasin plus TACE against TACE alone for unresectable HCC, but the actual findings are not presented in this abstract.